ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation
Lay Description
Category
- Heart, Vascular and Blood
- Urinary Tract and Kidney
- Inflammatory Diseases
- IRB Number
- 20210508HU
- NCT Number
- ct.gov registration not required
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- Eligible Genders
- Accepts Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Regulatory Point of Contact
Shweta Bansal
2100-567-5338
bansals3@uthscsa.edu
Regulatory Point of Contact
Aliseiya Garza
(210) 567-4700
garzaa35@uthscsa.edu
Regulatory Point of Contact
Myriam Gonzalez
(210) 562-6516
gonzalezm38@uthscsa.edu
Regulatory Point of Contact
Monique Johnson
JohnsonM13@uthscsa.edu
Regulatory Point of Contact
Jonathan Polanco
(210) 567-0136
polancoj@uthscsa.edu
Local Recruitment Point of Contact
Shweta Bansal
2100-567-5338
bansals3@uthscsa.edu
Local Recruitment Point of Contact
Aliseiya Garza
(210) 567-4700
garzaa35@uthscsa.edu
Principal Investigator
Shweta Bansal